NewsEvents

Your Yourlocation: Home > Effects of tiotropium bromide(136310-93-5) combined with noninvasive ventilation on pulmonary function in patients with stable chronic obstructive pulmonary disease

The authors published a paper to investigate the effect of tiotropium bromide(136310-93-5) combined with noninvasive ventilation on lung function in patients with chronic obstructive pulmonary disease (COPD) at stable phase and to provide evidence for the treatment of chronic obstructive pulmonary disease (COPD). Titropium bromide combined with noninvasive ventilation treatment of chronic obstructive pulmonary disease in patients with stable phase can improve lung function and improve the quality of life of patients, fewer adverse reactions, and its role in reducing inflammation and expression of the article published on "Chinese Journal of chronic diseases prevention and control" 2015 Vol 23.

72 patients with stable chronic obstructive pulmonary disease were randomly divided into two groups: tiotropium bromide(136310-93-5) group (treatment group) and seretide treatment group (control group), 36 cases in each group, the two groups were given early non-invasive ventilation, (FEV1), 1s forced expiratory volume (FEV1 /FVC), and forced expiratory volume (FEV1 /FVC) in the two groups were observed and compared with those in the control group. After 3 months of continuous treatment, the control group was given adjuvant tiotropium bromide(136310-93-5). Serum interleukin (IL) 6 and IL-10 levels as well as the incidence of adverse reactions.

The FEV1 and FEV /FVC of FEV1 and FEV1 / FVC of the two groups were significantly higher than those of the control group after treatment (P <0.05) .There was significant difference between the two groups (P> 0.05). After treatment, the levels of serum IL-6 and IL-10 in the treatment group were significantly lower than those before treatment (P <0.05) And the level of IL-10 in the treatment group were significantly lower than those in the control group (P <0.05) .After treatment, the symptoms, activity and daily life scores of the treatment group were (78.93 ± 7.10), (85.39 ± 7.22) (89.34 ± 7.18), (91.63 ± 7.44), (94.38 ± 8.22)], respectively.There was significant difference between the two groups (P <0.05) .Compared with the control group, Patients with dry mouth, urinary retention, pharyngeal discomfort, tachycardia and other adverse events compared with the control group, the difference was not statistically significant (P> 0.05).

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved